Literature DB >> 15917570

Caspofungin in combination with amphotericin B against Candida glabrata.

Francesco Barchiesi1, Elisabetta Spreghini, Annette W Fothergill, Daniela Arzeni, Gianfranco Greganti, Daniele Giannini, Michael G Rinaldi, Giorgio Scalise.   

Abstract

The effects of caspofungin combined with amphotericin B were investigated with Candida glabrata. Although in vitro experiments showed an indifferent interaction, the combination regimen was the only therapeutic approach yielding organ sterilization in a murine candidemia model.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15917570      PMCID： PMC1140549          DOI： 10.1128/AAC.49.6.2546-2549.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

Review 1.  Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.

Authors:  M A Pfaller; D J Sheehan; J H Rex
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

Review 2.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

3.  Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC).

Authors:  C Viscoli; C Girmenia; A Marinus; L Collette; P Martino; B Vandercam; C Doyen; B Lebeau; D Spence; V Krcmery; B De Pauw; F Meunier
Journal:  Clin Infect Dis       Date:  1999-05       Impact factor: 9.079

4.  Nosocomial bloodstream infections in United States hospitals: a three-year analysis.

Authors:  M B Edmond; S E Wallace; D K McClish; M A Pfaller; R N Jones; R P Wenzel
Journal:  Clin Infect Dis       Date:  1999-08       Impact factor: 9.079

5.  Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans.

Authors:  Mohammad A Hossain; Guadalupe H Reyes; Lisa A Long; Pranab K Mukherjee; Mahmoud A Ghannoum
Journal:  J Antimicrob Chemother       Date:  2003-04-25       Impact factor: 5.790

6.  Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002.

Authors:  M A Pfaller; S A Messer; L Boyken; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

Review 7.  Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans.

Authors:  P L Fidel; J A Vazquez; J D Sobel
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

8.  Caspofungin.

Authors:  Stanley C Deresinski; David A Stevens
Journal:  Clin Infect Dis       Date:  2003-05-19       Impact factor: 9.079
  8 in total
  9 in total

1.  Antifungal activity of caspofungin in combination with amphotericin B against Candida glabrata: comparison of disk diffusion, Etest, and time-kill methods.

Authors:  Nuri Kiraz; Ilknur Dag; Mustafa Yamac; Abdurrahman Kiremitci; Nilgun Kasifoglu; Yurdanur Akgun
Journal:  Antimicrob Agents Chemother       Date:  2008-11-24       Impact factor: 5.191

2.  Activity of Combined Antifungal Agents Against Multidrug-Resistant Candida glabrata Strains.

Authors:  Laura Bedin Denardi; Jéssica Tairine Keller; Vanessa Oliveira; Débora Alves Nunes Mario; Janio Morais Santurio; Sydney Hartz Alves
Journal:  Mycopathologia       Date:  2017-05-10       Impact factor: 2.574

3.  Effects of antifungal agents alone and in combination against Candida glabrata strains susceptible or resistant to fluconazole.

Authors:  Izabel Almeida Alves; Laíssa Arévalo Bandeira; Débora Alves Nunes Mario; Laura Bedin Denardi; Louise Vignoles Neves; Janio Morais Santurio; Sydney Hartz Alves
Journal:  Mycopathologia       Date:  2012-04-22       Impact factor: 2.574

4.  Caspofungin in combination with amphotericin B against Candida parapsilosis.

Authors:  Francesco Barchiesi; Elisabetta Spreghini; Serena Tomassetti; Daniele Giannini; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2006-12-11       Impact factor: 5.191

5.  Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients.

Authors:  Andreas H Groll; Gerda Silling; Charlotte Young; Rainer Schwerdtfeger; Helmut Ostermann; Werner J Heinz; Joachim Gerss; Hedwig Kolve; Claudia Lanvers-Kaminsky; João Paulo Vieira Pinheiro; Sibylle Gammelin; Oliver A Cornely; Gudrun Wuerthwein
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

6.  Increases in SLT2 expression and chitin content are associated with incomplete killing of Candida glabrata by caspofungin.

Authors:  Jason M Cota; Jodi L Grabinski; Robert L Talbert; David S Burgess; P David Rogers; Thomas D Edlind; Nathan P Wiederhold
Journal:  Antimicrob Agents Chemother       Date:  2007-12-17       Impact factor: 5.191

7.  Limitations of caspofungin in the treatment of obstructive pyonephrosis due to Candida glabrata infection.

Authors:  Silke Schelenz; Calum N Ross
Journal:  BMC Infect Dis       Date:  2006-08-08       Impact factor: 3.090

8.  Multicenter Collaborative Study of the Interaction of Antifungal Combinations against Candida Spp. by Loewe Additivity and Bliss Independence-Based Response Surface Analysis.

Authors:  Joseph Meletiadis; David R Andes; Shawn R Lockhart; Mahmoud A Ghannoum; Cindy C Knapp; Luis Ostrosky-Zeichner; Michael A Pfaller; Vishnu Chaturvedi; Thomas J Walsh
Journal:  J Fungi (Basel)       Date:  2022-09-16

9.  Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence.

Authors:  Sélène Ferrari; Françoise Ischer; David Calabrese; Brunella Posteraro; Maurizio Sanguinetti; Giovanni Fadda; Bettina Rohde; Christopher Bauser; Oliver Bader; Dominique Sanglard
Journal:  PLoS Pathog       Date:  2009-01-16       Impact factor: 6.823
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.